307 related articles for article (PubMed ID: 6662682)
1. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit.
Wielunsky E; Drucker M; Cohen T; Reisner SH
Isr J Med Sci; 1983 Nov; 19(11):1006-8. PubMed ID: 6662682
[TBL] [Abstract][Full Text] [Related]
2. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
[No Abstract] [Full Text] [Related]
3. An epidemic oc gentamicin/cloxacillin resistant staphylococcal infection in a neonatal unit.
Mulhern B; Griffin E
Ir Med J; 1981 Aug; 74(8):228-9. PubMed ID: 7319781
[No Abstract] [Full Text] [Related]
4. Antibiotic resistance patterns during aminoglycoside restriction.
Young EJ; Sewell CM; Koza MA; Clarridge JE
Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
[TBL] [Abstract][Full Text] [Related]
5. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
Sklaver AR; Greenman RL; Hoffman TA
Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
[TBL] [Abstract][Full Text] [Related]
6. Gentamicin resistance among gram-negative bacillary blood isolates in a hospital with long-term use of gentamicin.
Mylotte JM
Arch Intern Med; 1987 Sep; 147(9):1642-4. PubMed ID: 3307673
[TBL] [Abstract][Full Text] [Related]
7. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit.
Toltzis P
Minerva Pediatr; 2003 Oct; 55(5):385-93. PubMed ID: 14608262
[TBL] [Abstract][Full Text] [Related]
8. Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.
Cross AS; Opal S; Kopecko DJ
Arch Intern Med; 1983 Nov; 143(11):2075-80. PubMed ID: 6639227
[TBL] [Abstract][Full Text] [Related]
9. Clinical and microbiologic consequences of amikacin use during a 42-month period.
Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
[TBL] [Abstract][Full Text] [Related]
10. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
Leonard JM; McGee ZA; Alford RH
Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study and time changes in the resistance to gentamycin, tobramycin, sisomicin and amikacin of Gram-negative nosocomial bacterial strains isolated from the urinary tract, in relation to the annual use of the aminoglycosides tested].
Alegente G; Marchi B; Pieri I; Saturni A; Progenie G; Rubino M
Quad Sclavo Diagn; 1983 Sep; 19(3):343-8. PubMed ID: 6677931
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of gram-negative conjunctivitis in neonatal intensive care unit patients.
Chen CJ; Starr CE
Am J Ophthalmol; 2008 Jun; 145(6):966-970. PubMed ID: 18378213
[TBL] [Abstract][Full Text] [Related]
13. Molecular typing demonstrating transmission of gram-negative rods in a neonatal intensive care unit in the absence of a recognized epidemic.
Almuneef MA; Baltimore RS; Farrel PA; Reagan-Cirincione P; Dembry LM
Clin Infect Dis; 2001 Jan; 32(2):220-7. PubMed ID: 11170911
[TBL] [Abstract][Full Text] [Related]
14. Outbreak of amikacin-resistant Enterobacteriaceae in an intensive care nursery.
Cook LN; Davis RS; Stover BH
Pediatrics; 1980 Feb; 65(2):264-8. PubMed ID: 6986597
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic-resistant organisms in the neonatal intensive care unit.
Bizzarro MJ; Gallagher PG
Semin Perinatol; 2007 Feb; 31(1):26-32. PubMed ID: 17317424
[TBL] [Abstract][Full Text] [Related]
16. The elimination of gentamicin-resistant gram-negative bacteria in a newborn intensive care unit.
Raz R; Sharir R; Shmilowitz L; Kenes I; Ephros M
Infection; 1987; 15(1):32-4. PubMed ID: 3646180
[TBL] [Abstract][Full Text] [Related]
17. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
Saavedra S; Vera D; Ramírez-Ronda CH
Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
[TBL] [Abstract][Full Text] [Related]
19. Controlled comparison of amikacin and gentamicin.
Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
[TBL] [Abstract][Full Text] [Related]
20. Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.
Faragó E; Kiss J; Gömöry A; Aranyosi J; Juhász I; Mihóczy L
Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):421-8. PubMed ID: 511416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
